The outlook of companies tied to Viagra's history presents a challenging investment picture . While the initial boom generated substantial profits , generic alternatives have significantly eroded revenue. Investing in related pharmaceutical businesses now requires a careful assessment of patent safeguards, evolving patient shifts , and the prospect